Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7817956 | 0.88 | POLB (0.59) | POLBLMNASMN1; SMN2L3MBTL1RXFP1 | |
| SCHEMBL3019686 | 0.83 | NCEH1 (0.58) | POLBLMNASMN1; SMN2L3MBTL1RXFP1 | |
| SCHEMBL30638066 | 0.83 | MAPT (0.55) | POLBLMNASMN1; SMN2L3MBTL1RXFP1 | |
| SCHEMBL3829305 | 0.83 | MAPT (0.55) | POLBLMNASMN1; SMN2L3MBTL1RXFP1 | |
| SCHEMBL5749500 | 0.81 | IDO1 (0.57) | POLBLMNASMN1; SMN2L3MBTL1RXFP1 | |
| SCHEMBL806517 | 0.81 | ACHE (0.54) | POLBLMNAL3MBTL1KMT2AKDM4E | |
| SCHEMBL29262551 | 0.81 | RXFP1 (0.63) | POLBLMNASMN1; SMN2L3MBTL1RXFP1 | |
| SCHEMBL3160115 | 0.80 | POLB (0.50) | POLBLMNASMN1; SMN2L3MBTL1RXFP1 | |
| SCHEMBL8395861 | 0.80 | POLB (0.50) | POLBLMNASMN1; SMN2L3MBTL1RXFP1 | |
| SCHEMBL13781592 | 0.80 | NCEH1 (0.60) | POLBLMNASMN1; SMN2L3MBTL1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114015459-A | Double-naphthalene monomer-containing liquid crystal and preparation method and application thereof | 中节能万润股份有限公司 | 2022-02-08 | — | — | CN | claimed |
| CN-114015459-B | Liquid crystal containing dinaphthyl monomer, and preparation method and application thereof | 中节能万润股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-114015459-A | Double-naphthalene monomer-containing liquid crystal and preparation method and application thereof | 中节能万润股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| EP-3242872-B1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| EP-3242872-A1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2016112284-A1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016112284-A1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| US-7959990-B2 | Adjustment of liquid crystals; oligomers, dendrimers, or polymer in solution is applied to support; crosslinking by radiation or polarized light | ROLIC AG (CH) | 2011-06-14 | — | — | US | disclosed |
| US-20080274304-A1 | Functionalized Photoreactive Compounds | ROLIC AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20030236274-A1 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6573289-B1 | Naphthalene derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1073640-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| EP-0710367-B1 | PHOTOCHROMIC SUBSTITUTED NAPHTHOPYRAN COMPOUNDS | PPG IND OHIO INC (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999054309-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| US-5637262-A | REVERSIBLE PHOTOCHROMIC DYES FOR OPHTHALMIC LENSES | TRANSITIONS OPTICAL, INC. (US) | 1997-06-10 | — | — | US | disclosed |
| EP-0710367-A4 | — | — | 1996-05-15 | — | — | EP | disclosed |
| EP-0710367-A1 | PHOTOCHROMIC SUBSTITUTED NAPHTHOPYRAN COMPOUNDS | PPG INDUSTRIES, INC. (US) | 1996-05-08 | — | — | EP | disclosed |
| US-5466398-A | Photochromic substituted naphthopyran compounds | TRANSITIONS OPTICAL, INC. (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995000867-A1 | PHOTOCHROMIC SUBSTITUTED NAPHTHOPYRAN COMPOUNDS | PPG INDUSTRIES, INC. (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236274-A1 | Naphthalene derivatives, their production and use | CYP17A1, CYP21A2, HSD17B1 | POLB 2225/4885LMNA 3058/4885SMN1; SMN2 3733/4885 |
| US-20080274304-A1 | Functionalized Photoreactive Compounds | PCNA, PIN1, MAP1LC3C | POLB 610/4885LMNA 1132/4885SMN1; SMN2 4506/4885 |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | POLB 810/4885LMNA 1915/4885SMN1; SMN2 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.